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Candida infections are a leading cause of infectious disease-related death in children supported by extracorporeal membrane
oxygenation (ECMO). The ECMO circuit can alter drug pharmacokinetics (PK); thus, standard fluconazole dosing may result in
suboptimal drug exposures. The objective of our study was to determine the PK of fluconazole in children on ECMO. Forty chil-
dren with 367 PK samples were included in the analysis. The PK data were analyzed using nonlinear mixed-effect modeling
(NONMEM). A one-compartment model best described the data. Weight was included in the base model for clearance (CL) and
volume of distribution (V). The final model included the effect of serum creatinine (SCR) level on CL and the effect of ECMO on
V as follows: CL (in liters per hour)  0.019  weight  (SCR/0.4)0.29  exp(CL) and V (in liters)  0.93  weight 
1.4ECMO  exp(V). The fluconazole V was increased in children supported by ECMO. Consequently, children on ECMO require
a higher fluconazole loading dose for prophylaxis (12 mg/kg of body weight) and treatment (35 mg/kg) paired with standard
maintenance doses to achieve exposures similar to those of children not on ECMO.
Extracorporeal membrane oxygenation (ECMO) is life-savingin children with refractory cardiorespiratory failure. ECMO is
a cardiopulmonary bypass device that provides complete respira-
tory and cardiac support. Mechanically, blood is drained from the
venous system, pumped through an artificial lung membrane in
which oxygen is added and carbon dioxide is removed, and then
returned to either venous or arterial circulation. ECMO has been
used successfully to support children with multiple disease pro-
cesses, including meconium aspiration syndrome, fulminant
myocarditis, and sepsis (1). Despite these successes, children sup-
ported by ECMO are at high risk for ECMO-related complica-
tions, especially nosocomial infections (2).
Invasive candidiasis is common and fatal in children on
ECMO. In this population, Candida species are the most common
infectious organism (2). The incidence of infection varies by cen-
ter, and rates as high as 10% have been reported (2, 3). Candida
infections cause substantial morbidity and mortality (3) and are
difficult to eradicate due to the ability of the organism to adhere to
indwelling catheters. For this reason, routine management of can-
didiasis consists not only of the use of antifungal agents but also
the removal of catheters (4). Catheter removal for children on
ECMO is often impossible, because the ECMO cannulas connect
the child to the ECMO circuit. Therefore, therapy on ECMO relies
on either the prevention of invasive candidiasis or optimal thera-
peutic dosing in children with infection.
Optimal dosing for prevention or treatment of candidiasis in
children on ECMO can differ greatly from that with other popu-
lations due to the pharmacokinetic (PK) changes induced by the
ECMO circuit. PK changes attributed to ECMO support include
increased volume of distribution (V) and decreased clearance
(CL), but these vary by drug and are not consistently predicted
using drug physicochemical properties (5–8). This study describes
the population PK of fluconazole in children supported by ECMO
and provides rational dosing recommendations for the preven-
tion and treatment of invasive candidiasis in this vulnerable pop-
ulation.
MATERIALS AND METHODS
Study design. Fluconazole samples were obtained from three prospective
trials. Study 1 was a single-center open-label PK study of fluconazole in
children on ECMO (n  20) (9), study 2 was a single-center PK study of a
fluconazole loading dose in critically ill children (n  12) (10), and study
3 was a multicenter PK study of fluconazole in infants (n  8) (11). The
study designs are described in detail elsewhere (9–11). In brief, study 1
included critically ill children 18 years of age supported by ECMO who
received intravenous (i.v.) fluconazole (25 mg/kg of body weight once
weekly for prophylaxis or standard-of-care dosing for presumed fungal
infection) for the prevention or treatment of fungal infection. Study 2
included critically ill infants 1 year of age, one of whom was supported
by ECMO, who received a fluconazole loading dose (25 mg/kg i.v. once),
followed by daily maintenance therapy (12 mg/kg i.v.). Study 3 enrolled
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infants from 23 to 42 weeks gestational age at birth who were 120 days of
age and receiving i.v. fluconazole for the prevention or treatment of can-
didiasis. We included only the children from study 3 who were 36 weeks
gestation to limit the PK variability introduced by prematurity. These
trials were approved by the respective institutional review boards, and
written informed consent was obtained from the legal guardian of each
child.
The following clinical variables were collected for all studies: postnatal
age (PNA), weight, race, sex, presence of ECMO support, use of hemofil-
tration or dialysis, and serum creatinine (SCR) levels. Serum albumin,
aspartate aminotransferase (AST), and serum alanine aminotransferase
(ALT) data were collected for studies 1 and 2. PNA and weight were
calculated on the day of the first dose of study drug, and those values were
imputed forward. For children with multiple measurements of SCR, al-
bumin, AST, or ALT, values were allowed to change with time. For chil-
dren without albumin, AST, or ALT measurements during the study pe-
riod, the values were set to the population medians (2.7 g/dl, 35 U/liter,
and 19 U/liter, respectively). A comparison of the covariate values be-
tween children on ECMO and those not on ECMO was done using the
Wilcoxon rank sum test in Stata 12 (StataCorp, College Station, TX).
PK sample collection. Children in study 1 had up to 12 plasma sam-
ples (200 l each) collected around doses 1 and 2. The sampling windows
at each dose included 0 to 4 h prior to the start of infusion and serial
samples after the end of the infusion at 15 min (15 min), 3 h (1 h), 9 h
(3 h), 23 h (1 h), and 47 h (1 h). Children in study 2 had 6 to 8
plasma samples (200 l each) after the loading dose at the following time
points after the end of the infusion: 15 min (15 min), 3 h (1 h), 9 h (3
h), and 21 h (3 h), and multidose sampling occurred after doses 3 and 5
(0 to 4 h before dose and 2 to 6 h after dose). Infants enrolled in study 3
were sampled preinfusion, at the end of infusion, and 1 h, 7 h (1 h) or 11
h (1 h), 24 h, and 48 h postinfusion. Samples were collected in BD EDTA
Microtainers and taken from a different site than the site used for flucona-
zole administration. The samples were processed immediately or placed
on ice until processing. Plasma was separated via centrifugation (at
3,000  g and 4°C for 10 min), manually aspirated, and transferred to
polypropylene tubes. The plasma samples were frozen at 80°C until
analysis. To supplement these PK samples, plasma from leftover clinical
samples collected per standard of care (EDTA Microtainers) was collected
up to 72 h after sample collection. Fluconazole scavenge samples have
been shown to be stable for up to 72 h (11).
Analytic procedures. Plasma fluconazole concentrations were deter-
mined using a validated liquid chromatography-tandem mass spectrom-
etry assay (12). The lower limit of quantification was 0.01 mg/liter; intra-
day and interday precision rates ranged from 2.84% to 10.8% and 5.27%
to 11.5%, respectively, within the concentration range of the standard
curve (0.01 to 10 mg/liter).
Population PK analysis. PK data were analyzed with a nonlinear
mixed-effect modeling approach using NONMEM version 7.2 (Icon De-
velopment Solutions, Ellicott City, MD) in conjunction with Perl speaks
NONMEM version 3.6.2 (13). Run management was performed using
Piraña version 2.8.0 (14). Model analysis was summarized with Stata 12
(StataCorp, College Station, TX). A first-order conditional estimate with
interaction was used for all models. One- and two-compartment PK
structural models were evaluated. Interindividual random effects were
evaluated on CL and V, and both diagonal and block Omega matrices for
covariance were explored. An exponential model for interindividual vari-
ance was used. The eta shrinkage was assessed to determine if the PK data
set was informative to adequately estimate interindividual variability in
PK parameter estimates. Proportional and additive-plus-proportional er-
ror models of residual variability were assessed. Body weight was incor-
porated into the base model before the evaluation of other covariates due
to multicolinearity with other clinical covariates. Both linear and allomet-
ric scaling of weight was assessed for clearance. For volume and intercom-
partmental clearance parameters, size-based scaling was incorporated us-
ing a linear relationship with body weight. The impact of physiologically
plausible covariates was evaluated if a relationship was suggested by visual
inspection of scatter and box plots (for continuous and categorical vari-
ables, respectively) of individual Bayesian estimates of CL and V obtained
from the base model against covariates. The following covariates were
evaluated: ECMO support, volume of blood required to prime the ECMO
circuit, ratio of blood prime volume to the estimated native blood volume
of the child, hemofiltration, use of continuous venovenous hemodialysis
(CVVHD), SCR, albumin, AST, and ALT levels, PNA, sex, and race. All
continuous variables were centered using the median value. Covariate
testing was performed via standard stepwise forward addition, backward
elimination methods. Covariates were included in the multivariable anal-
ysis if the decrease in the objective function value relative to the base
model was 3.84 (P  0.05). Covariates were retained in the final model
if their removal from the multivariable model caused an increase in the
objective function value of 6.635 (P  0.01). Empirical Bayesian esti-
mates of individual PK parameters were generated from the final model
using the post hoc subroutine.
Model evaluation. Models were evaluated based on the successful
minimization, goodness-of-fit plots, objective function values, plausibil-
ity of parameter estimates, and precision of parameter estimates. The
precision of the final model was evaluated through bootstrapping with
1,000 replicate data sets to generate median and 95% confidence intervals
for the PK parameter estimates. In addition, a visual predictive check was
used to evaluate model predictability by simulating 1,000 data sets based
on the final parameter estimates and their associated variances. The dos-
ing and covariate values used to generate the predictions in the standard-
ized visual predictive check were the same as those used in the study
population. The simulated results were compared with the results ob-
served in the study, and the number of observed concentrations outside
the 90% prediction interval was quantified.
Assessment of dose-exposure relationship. Fluconazole exhibits
time-dependent fungistatic activity with a prolonged postantibiotic effect,
and efficacy is most closely associated with an area under the concentra-
tion-time curve (AUC) to MIC ratio (AUC/MIC) of 50 (15–17). For
treatment, we chose to target a minimum AUC for the first 24 h (AUC24)
of 400 mg · h/liter in 90% of the children. The AUC24 of 400 mg · h/liter
achieves the target AUC/MIC ratio, assuming an MIC of 8 mg/liter, the
Clinical and Laboratory Standards Institute (CLSI) sensitivity breakpoint
for all Candida species (18). There are no established pharmacodynamic
targets for prophylaxis, so we chose an AUC24 of 200 mg · h/liter in 90% of
the simulated children to match the exposure seen in adults on 200 to 400
mg daily for prophylaxis (19–21). For prophylaxis, it is important to min-
imize the development of Candida resistance. The risk of developing re-
sistance increases when fluconazole concentrations are below the MIC for
50% of the dosing interval (22). Therefore, for prophylaxis, we also
evaluated as a secondary endpoint the percentage of the dosing interval
that concentrations were above the MIC (%TMIC).
Monte Carlo simulations using parameter estimates from the final
model were used to explore dose-exposure relationships using these tar-
gets. We explored a variety of dosing regimens based on current Infectious
Diseases Society of America (IDSA) guidelines (19) and our previous
work describing fluconazole exposure in children on ECMO (9). We sim-
ulated 100 PK profiles for each child in the data set based on the parameter
estimates and the variability derived from the final model to measure
target attainment rates in the first 24 h and at steady state. We stratified
children by the presence or absence of ECMO support. Using parameter
estimates from the final model, we calculated the maximum (Cmax) and
minimum (Cmin) fluconazole concentrations for each of 14 simulated
dosing intervals using the equation for an intermittent infusion. We then
used the Cmax and Cmin values to calculate the AUC for each dosing inter-
val using the linear-up log-down trapezoidal approach.
RESULTS
Study infants and PK specimens. PK samples were collected from
40 children who received intravenous (i.v.) fluconazole. The me-
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dian age of the children was 22 days (range, 1 day, 17 years) (Table
1). While some children were born prematurely, the median post-
menstrual age for children 1 year of age was 41 weeks (range, 35,
76 weeks). Data from 360 plasma PK samples with a median of 8
samples per child (range, 1, 22 samples) were included in the pop-
ulation PK analysis. Fifty-five (15%) of the PK samples were scav-
enge samples (study 1, n  32; study 2, n  6; study 3, n  17).
Twenty-one (53%) children were supported by ECMO. Five of the
children on ECMO had concomitant hemofiltration during PK
sample collection, and two of those children subsequently re-
quired CVVHD. The median number of SCR samples collected
during the study period per child was 10 (range, 1, 23 samples). All
children had an SCR sample at time of first dose. The median SCR
level at the time of first dose was 0.4 mg/dl (range, 0.1, 1.3 mg/dl),
and the maximum SCR level during the PK sampling period was
0.6 mg/dl (range, 0.1, 3.2 mg/dl). The initial SCR level was not
significantly different between children on ECMO and those not
on ECMO (0.5 versus 0.3 mg/dl, respectively; P  0.13). However,
children on ECMO had a higher maximum SCR level than that of
children not on ECMO (0.7 versus 0.5 mg/dl, respectively; P 
0.03). Albumin and AST/ALT lab values were available for all chil-
dren on ECMO but only for half of those not on ECMO. The
median albumin levels were low, at 2.7, whereas the AST/ALT
levels were within normal limits (Table 1). No children developed
culture-confirmed invasive candidiasis while on the study.
Population PK model development. A summary of the model
building process is shown in Table 2. Based on goodness-of-fit
criteria, a one-compartment model best described the data.
Weight was included in the base model for CL and V. CL and V
were not correlated, and use of a covariance term between CL and
V did not improve the model fit. The eta shrinkage of the base
model was low for both CL (4.6%) and V (7.0%), allowing us to
reliably estimate interindividual variability for both parameters.
Similarly, the eps shrinkage was low, at 9.6%, suggesting that our
model was not overparameterized. Residual variability was best
described by a proportional error model. While a proportional-
plus-additive error model resulted in a significant drop in the
objective function, we were unable to precisely estimate the addi-
tive error component. Because goodness-of-fit plots and estimates
were virtually identical between the two error models, we used the
proportional error model in the final model. Allometric scaling of
weight (3/4 power) on CL did not improve model fit and increased
the objective function value by 9.7 points. Similarly, the use of a
sigmoidal maximum effect (Emax) maturation relationship be-
tween postmenstrual age and CL resulted in an increase in the
objective function value by 4.8 points. Consequently, weight was
scaled to the power of 1 for both CL and V. The residual unex-
plained interindividual variability in CL was visually associated
with SCR level, hemofiltration, CVVHD, and albumin level, while
ECMO support, hemofiltration, and CVVHD were associated
with interindividual variability in V. During the univariable anal-
ysis, SCR level and hemofiltration on CL and ECMO and hemo-
filtration on V resulted in a significant drop in the objective func-
tion and were included in the multivariable analysis. Neither
ECMO prime volume nor the ratio of prime volume to native
blood volume improved the model fit on V better than presence of






n (%) 40 (100) 21 (53) 19 (47)
Body wt (kg) 3.4 (1.9, 77) 4.2 (2.0, 77) 3.2 (1.9, 8.0)
Postnatal age (days) 22 (1, 6,498) 113 (1, 6,498) 13 (1, 262)
Gestational age (wk)b 38 (24, 41) 38 (30, 41) 37 (24, 40)
Postmenstrual age (wk) 41 (35, 76) 42 (36, 63) 39 (35, 76)
Female 14 (35) 7 (33) 7 (37)
Race
White 17 (43) 9 (43) 8 (42)
African-American 18 (45) 10 (48) 8 (42)
Other 5 (12) 2 (9) 3 (16)
Indication
Prophylaxis 23 (57) 17 (81) 6 (32)
Treatment 17 (43) 4 (19) 13 (68)
First dose (mg/kg) 25 (2.7, 26.5) 25.0 (10.4, 25.7) 17.4 (2.7, 26.5)
PK sample collection period (days)c 5.5 (2.0, 34.0) 8.8 (2.1, 21.3) 4.2 (2.0, 34.0)
No. of PK samples per child 8 (1, 22) 11 (5, 22) 8 (1, 14)
Serum creatinine level (mg/dl)
Initiald 0.4 (0.1, 1.3) 0.5 (0.1, 1.2) 0.3 (0.1, 1.3)
Maximum 0.6 (0.1, 3.2) 0.7 (0.3, 3.2) 0.5 (0.1, 1.3)
Albumin level (g/dl) 2.7 (1.1, 4.0) 2.8 (2.0, 4.0) 2.7 (1.1, 3.1)
Aspartate aminotransferase level (U/liter) 35 (15, 673) 39 (23, 673) 35 (15, 159)
Alanine aminotransferase level (U/liter) 19 (8, 127) 16 (8, 127) 19 (8, 126)
a Values are median (range) for continuous variables and no. (%) for categorical variables.
b Gestational age is reported only for infants 1 year of age (n  33).
c Sample collection period is the time between first dose of study drug and collection of last PK sample.
d Initial serum creatinine collected within 24 h of first dose.
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ECMO support. Because these covariates are colinear with
ECMO, we included only the effect of ECMO on V in the multi-
variable analysis. In the multivariable analysis, during the forward
addition step, the addition of SCR and hemofiltration to CL and
ECMO support and hemofiltration to V resulted in a significant
drop in the objective function. However, during backward elimi-
nation, hemofiltration on CL and V did not improve the model
goodness of fit, nor did it significantly decrease the objective func-
tion value. The final model included the effect of SCR on CL and
ECMO on V. CL (in liters per hour) was calculated as 0.019 
weight  (SCR/0.5)0.29  exp(	CL), and V (in liters) was calcu-
lated as 0.93  weight  1.4ECMO  exp(	V). 	CL and 	V refer to
the interindividual variability on CL and V, respectively. ECMO is
equal to 1 if ECMO is present and 0 if ECMO is not present.
Model evaluation and validation. The final model had good
precision, as evidenced by the % relative standard errors around
the parameter point estimates for fixed effects (5.6 to 9.9%) and
random effects (13.1 to 28.6%) and by 95% confidence intervals
generated by bootstrapping (n  1,000 simulated trials, 999 suc-
cessful runs) (Table 3). Goodness-of-fit diagnostic plots for the
final model are shown in Fig. 1. The visual predictive check dem-
onstrated a good fit between observed and predicted fluconazole
concentrations (Fig. 2). Only 4% (13/360) of the observed con-
centrations were outside the 90% prediction interval, with 10 ob-
servations greater than the prediction interval and 3 observations
below. Of the 3 subjects with observed data greater than the pre-
diction interval, one had the highest dose in the cohort (27 mg/kg
load, followed by 12 mg/kg daily), and the other two received a
high loading dose (25 mg/kg and 23 mg/kg, respectively, followed
by 12 mg/kg daily) in the context of mild to moderate renal dys-
function. The subject with 3 observations below the prediction
interval received the lowest dose of the cohort. None of these
children were on ECMO, and all were 2 years of age.
Empirical Bayesian estimates of CL and V. The median
(range) empirical Bayesian estimates for CL and V in children not
on ECMO were 0.018 liters/h/kg (0.008, 0.042 liters/h/kg) and
0.93 liters/kg (0.55, 1.37 liters/kg), respectively (Table 4). Children
on ECMO had 
45% higher V (median, 1.35 liters/kg; range,
0.81, 1.81 liters/kg) but similar CL (median, 0.018 liters/h/kg;
range, 0.011, 0.043 liters/h/kg) compared to those of children not
on ECMO. We saw a trend toward decreased impact of ECMO
support on V with increased age, likely reflecting the changing
relationship of ECMO prime volume (250 to 400 ml) to the native
blood volume of the child (
250 to 5,000 ml, depending on age).
Dose-exposure relationship. Monte Carlo simulations
TABLE 2 Population PK model developmenta
Model description Population modelb OFVc OFV
Base model and univariable analysisd
Volume of distribution (liters) V  V  wt 1,022.74
ECMO V  V  wt  1.41
ECMO( 1 or 0) 1,008.22 14.52
Hemofiltration V  V  wt  1.54
HMFLTR( 1 or 0) 1,012.13 10.61
Clearance (liters/h) CL  CL  wt 1,022.74
Creatinine CL  CL  wt  (creatinine/0.4)
0.29 950.84 71.91
Hemofiltration CL  CL  wt  0.66
HMFLTR 1,019.18 3.56
Multivariable analysis
CL  f(SCR), V  f(ECMO)e V  V  wt  1.39
ECMO 936.95 13.89f
CL  CL  wt  (creatinine/0.4)
0.29
CL  f(SCR), V  f(ECMO,HMFLTR) V  V  wt  1.30
ECMO  1.34HMFLTR 930.70 6.25g
CL  CL  wt  (creatinine/0.4)
0.29
CL  f(SCR, HMFLTR), V  f(ECMO, HMFLTR) V  V  wt  1.30
ECMO  1.34HMFLTR 930.33 0.37g
CL  CL  wt  (creatinine/0.4)
0.29  0.90HMFLTR
Final model
V  f(ECMO) V  V  wt  1.39
ECMO
CL  f(SCR) CL  CL  wt  (creatinine/0.4)
0.29 936.95 13.89f
a All coefficients in the models are estimated parameters from the respective model.
b V, volume of distribution; wt, weight; HMFLTR, hemofiltration; CL, clearance.
c OFV, objective function value.
d Only models of covariates that significantly improved the OFV are shown in the univariable analysis. For a full list of covariates tested, see Materials and Methods.
e SCR, serum creatinine.
f OFV calculated relative to CL
creatinine model (950.84).
g OFV calculated relative to preceding model.







V (liters/kg) 0.93 5.8 0.83 0.93 1.06
CL (liters/h/kg) 0.019 5.6 0.017 0.019 0.021
Coefficient for ECMO on V 1.39 7.8 1.17 1.39 1.63




22.2 28.6 14.7 21.5 27.7
CL interindividual variability
(CV [%])
33.2 21.3 25.0 32.6 39.2
Residual proportional error
(CV [%])
15.3 13.1 13.0 15.2 16.9
a RSE, residual standard error.
b CI, confidence interval.
c CV, coefficient of variation.
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showed that children both supported and not supported by
ECMO who received the IDSA-recommended treatment dose of
12 mg/kg daily (19) achieved the therapeutic target of an AUC24 of
400 mg · h/liter in 90% of the simulated children (Table 5). How-
ever, the time to reach therapeutic concentrations varied mark-
edly based on the loading dose. No children on ECMO receiving
12 mg/kg as the initial dose achieved the target of an AUC24 400
mg · h/liter in the first 24 h, and it took 10 days before 90% of the
simulated children had an AUC24 of 400 mg · h/liter. A loading
dose of 25 mg/kg achieved the therapeutic target within 24 h in
77.1% of the simulated children not on ECMO, but only 34.0% of
the children on ECMO reached the therapeutic target in the first
24 h with this loading dose. A loading dose of 35 mg/kg was re-
quired to achieve an AUC24 of 400 mg · h/liter in 87.7% of the
children on ECMO in the first 24 h, and 90% of the children
achieved the target by day 2. Providing either a 40-mg/kg loading
dose or 25 mg/kg every 12 h in the first day of therapy achieved an
AUC24 of 400 mg · h/liter in 95.4% and 90.8% of the children,
respectively, in the first 24 h. However, the maximum simulated
concentrations after the 40-mg/kg loading dose and the second
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FIG 2 Visual predictive check. The shaded area represents the 95% prediction
interval. The circles are observed data. The solid line represents the median of
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FIG 1 Final population PK model diagnostic plots: observed versus population prediction (A) and individual prediction (B) and weighted residuals versus
population predictions (C) and time (D). (A and B) Line of identity is included as a reference. For conditional weighted residuals (CWRES), a line at y  0 is
included as a reference.
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respectively) than that after a single loading dose of 35 mg/kg (54.6
mg/liter), raising concerns of toxicity (Table 5 and Fig. 3).
For prophylaxis, children on ECMO who received 6 mg/kg
daily per current IDSA guidelines did not achieve therapeutic ex-
posure (AUC24, 200 mg · h/liter in 90% of the children) until day
7 of therapy (Table 5). If children on ECMO receive a prophylactic
loading dose of 12 mg/kg, followed by 6 mg/kg daily, most
(68.9%) children will reach an AUC24 of 200 mg · h/liter by day
2, and 90.0% of the children will achieve the therapeutic AUC24 by
day 5 of therapy. We also simulated exposure using the prophy-
lactic dose evaluated in the ECMO fluconazole study (25 mg/kg,
once weekly) and found that this dosing regimen achieved the
target exposure during the first 2 days of the dosing interval, but
on days 3 to 7, only 65.9%, 33.8%, 14.5%, 5.8%, and 2.2% of the
children, respectively, achieved an AUC24 of 200 mg · h/liter. We
simulated 12 mg/kg every 72 h and found that even after 4 doses
(12 days), there were zero days when 90% of the children on
ECMO had an AUC24 of 200 mg · h/liter.
Because of the wide range of ages and weights among the study
subjects, the same treatment and prophylaxis simulations were
performed in children 2 years of age (data not shown). The
results from these simulations were within 5% of the results above.
DISCUSSION
Current treatment recommendations for invasive candidiasis are
inadequate for treatment in children supported by ECMO. For the
treatment of invasive candidiasis, we chose to target exposures
observed in critically ill adults taking 800 mg of fluconazole per
day. A dose of 12 mg/kg per day achieved therapeutic exposure in
children on ECMO, but it took 10 days to reach those concentra-
tions. In a critically ill child, this delay is unacceptable. Loading
doses are routinely used in adults, and in a prior analysis of one of
the trials included in the current study, a fluconazole loading dose
of 25 mg/kg appeared safe and achieved pharmacodynamic targets
in 90% of a small cohort of children (10). Because of the increased
V observed in children on ECMO, a higher loading dose (35 mg/
kg) was required to achieve comparable exposure. Clinicians must
balance the risk of subtherapeutic exposure against the risk of
toxicity. In adults, a dose of 1,600 mg per day and serum concen-
trations of 80 mg/liter were well tolerated (23). The simulated
90th percentile concentration following a loading dose of 35
mg/kg was 34.2 mg/liter, and after maintenance therapy with 12
mg/kg, it was 51.8 mg/liter at steady state. While loading doses of
40 mg/kg and 25 mg/kg every 12 h (q12) in the first 24 h also
achieved therapeutic exposure in children on ECMO, the simu-
lated 90th percentile concentration was closer to 80 mg/liter, lead-
ing us to choose 35 mg/kg as the optimum loading dose. The safety
of this loading dose should be prospectively evaluated in children.
Because invasive candidiasis is so difficult to treat in children
on ECMO, this population might benefit from antifungal prophy-
laxis. Pharmacodynamic targets are not well defined for prophy-
laxis, but IDSA guidelines recommend 200 to 400 mg per day in
immunocompromised and critically ill adults, equating to an
AUC24 of 200 to 400 mg · h/liter. In addition to achieving appro-
priate prophylactic exposure, consideration must be given to lim-
iting the development of resistance to fluconazole. In vitro studies
suggest that maintaining plasma concentrations above the MIC
for 50% of the dosing interval limits resistance, but it is unclear if
the length of the dosing interval impacts this assumption. The
ECMO fluconazole prophylaxis study included in this population
analysis evaluated a dose of 25 mg/kg given once weekly. While
almost all of these children maintained a fluconazole concentra-
tion above an MIC of 4 mg/liter for 50% of the dosing interval,
many were below the MIC for the remainder of the dosing interval
(3.5 days). Considering the uncertainty regarding how long flu-
conazole concentrations can remain below the MIC before the
risk of resistance increases, we also simulated multiple daily regi-
mens. Given the devastating results of invasive candidiasis in chil-
dren on ECMO and the safety profile of fluconazole, we recom-
mend routine fluconazole prophylaxis of 12 mg/kg on day 1 and 6
mg/kg/day while on ECMO in centers with a high incidence of
Candida infection. SCR levels should be monitored closely during
fluconazole administration, given the propensity of children on
ECMO to develop renal dysfunction.
The difference in fluconazole exposure in children on ECMO
compared to those not on ECMO is related to the increased V seen
in children on ECMO. Increased V is expected due to the large
volume of exogenous blood required to prime the circuit and the
TABLE 4 Bayesian estimates of V and CL overall and by age group
based on ECMO supporta
V or CL by
time ECMO No ECMO
V (liters/kg)
0–30 days 1.5 (1.3, 1.8) 0.96 (0.55, 1.4)
31 days–2 yr 1.2 (0.91, 1.6) 0.83 (0.72, 1.0)
2–17 yr 1.1 (0.81, 1.5)
All 1.3 (0.81, 1.8) 0.93 (0.55, 1.4)
CL (liters/h/kg)
0–30 days 0.018 (0.013, 0.043) 0.018 (0.008, 0.042)
31 days–2 yr 0.022 (0.011, 0.039) 0.017 (0.008, 0.029)
2–17 yr 0.014 (0.013, 0.029)
All 0.018 (0.011, 0.043) 0.018 (0.008, 0.042)
a Values are median (range).





















Treatment 12 q24 0 10
25 12 q24 34.0 8
35 12 q24 87.7 2
40 12 q24 95.4 1
25 q12h 12 q24 90.8 1
Prophylaxis 6 q24 0 7
12 6 q24 27.8 5
12 q72 27.8 —b
25 q168 99.9 —
a PD, pharmacodynamics. The PD target for treatment/therapeutic exposure is an
AUC24 of 400 mg · h/liter in 90% of the simulated children. The PD target for
prophylaxis is an AUC24 of 200 mg · h/liter in 90% of the simulated children.
b —, for q72h and q168h dosing, we set the target as an AUC24 of 200 mg · h/liter in
90% of the simulated children for each 24-h period during the dosing interval. Using
this approach, 90% of the simulated children never maintained an AUC24 of 200 mg ·
h/liter for each 24-h period.
Watt et al.
3940 aac.asm.org July 2015 Volume 59 Number 7Antimicrobial Agents and Chemotherapy
FIG 3 Simulated fluconazole plasma concentrations and exposure. (A and B) Treatment doses. (C to F) Prophylactic doses. (A) Simulated fluconazole plasma
concentrations in children on ECMO (35 mg/kg load) compared to children not on ECMO (25 mg/kg load). Both cohorts received 12 mg/kg daily as
maintenance. (B) Simulated fluconazole exposure in children on ECMO after different loading doses. The lines for individual dosing regimens represent the 10th
percentile of exposure (i.e., 90% of simulated children above the line). The horizontal dashed line represents the target AUC for therapy. (C and D) Simulated
fluconazole plasma concentrations (C) and exposure (D) in children on ECMO receiving 12 mg/kg load and then 6 mg/kg daily. (E and F) Simulated fluconazole
plasma concentrations (E) and exposure (F) in children on ECMO receiving 25 mg/kg once weekly. The solid line is the median, and the shaded regions represent
the 90% prediction interval. The dashed lines represent an MIC of 4 mg/liter (C and E) and the target AUC for prophylaxis (D and F). The AUC is calculated for
a 24-h period for all panels.
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physiology associated with critical illness (e.g., inflammation).
Our data suggest that as children age, the impact of ECMO sup-
port on V decreases, likely reflecting the volume of the ECMO
prime in relation to the native blood volume of the child. For a
3-kg infant, the circuit prime volume (250 to 400 ml) might ex-
ceed their native blood volume (
250 ml), while in a 70-kg ado-
lescent, the prime volume is 
8% of the child’s blood volume (
5
liters). Our data are limited by the fact that only five of the 40
children were 2 years of age, and all of these were on ECMO.
Empirical Bayesian estimates of V in these five children (median,
1.1 liters/kg [range, 0.8, 1.5 liters/kg]) were slightly higher than
estimates of V reported in children age 2 to 12 years (0.95 liters/kg)
(24) and critically ill adults (0.6 to 0.7 liters/kg) (21). Given the
severity of illness seen in our children and the contribution of the
ECMO prime, our estimates are reasonable. However, because
very few children in this study were 2 years, we recommend
caution in extrapolating our results to this older population. Fur-
ther study of the impact of ECMO on fluconazole V is warranted
in children 2 years of age. ECMO also can increase V through
adsorption of drug by the ECMO circuit; this is well described for
other drugs (8, 25). However, a previous analysis evaluating flu-
conazole extraction by the ECMO circuit showed that fluconazole
undergoes minimal adsorption by the circuit and is unlikely to
contribute to increased V (9).
In our model, CL decreased with increasing SCR level. This
relationship also was expected, as fluconazole is primarily ex-
creted by the kidneys. Renal insufficiency is common in children
supported by ECMO (1), but ECMO support itself was not signif-
icantly associated with changes in CL. When combined with the
observation that neither CL nor SCR was significantly different
between children on ECMO and those not on ECMO, these results
suggest that dosing modifications in children with renal insuffi-
ciency should adhere to label guidelines, regardless of ECMO sup-
port. The possible exception to this conclusion is when ECMO is
combined with hemofiltration or CVVHD. Studies in adults show
that fluconazole CL increases in the presence of hemofiltration
and CVVHD (26–29). Only 5 children received hemofiltration,
and two received CVVHD, limiting our ability to draw conclu-
sions about their impact on CL. We recommend caution in ex-
trapolating our results to children on concomitant ECMO and
hemofiltration or CVVHD.
Conclusion. Fluconazole V is increased in children supported
by ECMO. As a result, children on ECMO who develop invasive
candidiasis require a fluconazole loading dose of 35 mg/kg, fol-
lowed by a daily maintenance dose of 12 mg/kg to achieve expo-
sures similar to those in children not on ECMO who are loaded
with 25 mg/kg and maintained on 12 mg/kg daily. Children on
ECMO may benefit from antifungal prophylaxis, and in this pop-
ulation, a loading dose of 12 mg/kg followed by 6 mg/kg daily is
reasonable based on adult exposures after 200 to 400 mg per day.
Children 2 years of age are underrepresented in this study, and
the results of the present study should be extrapolated to this
population with caution. In addition, these results are based on
simulated clinical trials. Confirmatory prospective trials of flu-
conazole exposure, safety, and efficacy at these doses in this pop-
ulation are needed.
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